logiko digit wrist-type automatic digital blood pressure meter
otos ortopedska tehnika d.o.o. vukovarska 1 31000 osijek -
utega s čeličnim perom
otos ortopedska tehnika d.o.o. vukovarska 1 31000 osijek -
schanzova kravata - plastika
otos ortopedska tehnika d.o.o. vukovarska 1 31000 osijek -
ortopedski uložak uni relax
otos ortopedska tehnika d.o.o. vukovarska 1 31000 osijek -
logiko master digital desk type sphyngomanometer
otos ortopedska tehnika d.o.o. vukovarska 1 31000 osijek -
manžeta za imobilizaciju trupa
otos ortopedska tehnika d.o.o vukovarska 1 31000 osijek -
schanzova kravata - plastika
otos ortopedska tehnika d.o.o. vukovarska 1 31000 osijek -
zeposia
bristol-myers squibb pharma eeig - ozanimod hidroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresivi - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
nexpovio
stemline therapeutics b.v. - selinexor - multipli mijelom - antineoplastična sredstva - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.